Neuroprotective agents are therapeutic compounds designed to preserve neuronal structure and function against injury or degeneration. They work by counteracting oxidative stress, excitotoxicity, mitochondrial dysfunction, and apoptosis — mechanisms commonly involved in neurological disorders.

The Neuroprotective Agents session highlights pharmacological, nutraceutical, and molecular approaches that safeguard neurons in stroke, Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury. It explores preclinical and clinical studies demonstrating the efficacy of antioxidant, anti-inflammatory, and metabolic modulators.

At the Neuroprotective Agents Conference, pharmacologists, neurologists, and translational scientists discuss how multi-target strategies and drug repurposing accelerate discovery. Focus areas include neurotrophic factors, peptide therapies, and bioactive plant compounds enhancing resilience.

This session is invaluable for clinicians, researchers, and biotech professionals developing novel CNS drugs. Attendees gain insights into mechanistic targets, delivery systems, and combination therapies supporting neurorestoration.

Recent findings in Experimental Neurotherapeutics reveal promising roles for mitochondrial stabilizers and nanocarriers in enhancing blood–brain-barrier penetration and neuroprotection durability.